Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

Acta Neurologica Scandinavica

Volumn 97, Issue 4, 1998, Pages 244-250

  Cutler, N R ^a   Polinsky, R J ^b   Sramek, J J ^a   Enz, A ^b   Jhee, S S ^a   Mancione, L ^b   Hourani, J ^a   Zolnouni, P ^a  

^a CALIFORNIA CLINICAL TRIALS   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Cerebrospinal fluid; Clinical trials; Rivastigmine; SDZ ENA 713

Indexed keywords

CHOLINESTERASE INHIBITOR; ENZYME INHIBITOR; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CHOLINERGIC NERVE CELL; CHOLINERGIC TRANSMISSION; CLINICAL ARTICLE; COGNITION; DOSE CALCULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; MALE; PATHOGENESIS;

EID: 0031897295     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb00645.x     Document Type: Article

References (25)

1. WHITEHOUSE PJ, PRICE DL, CLARK AW, COYLE JT, DELONG MR. Alzheimer's disease: evidence for selective loss of cholincrgic neurons in the nucleus hasalis. Ann Neurol 1981: 10: 122-6.
2. WHITEHOUSE PJ, PRICE DL, STRUBLE RG et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982: 215: 1237-9.
3. ASTHANA S, RAFFAELE KC, BERARDI A et al. Treatment of Alzheimer's disease by continuous intravenous infusion of physostigmine. Alzheimer Dis Assoc Disord 1995: 9: 223-32.
4. KNAPP MJ, KNOPMAN DS, SOLOMON PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994: 271: 985-91.
5. GRACON SI. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies. Acta Neurol Scand Suppl 1996: 165: 114-22.
6. ENZ A, AMSTUTZ R, BODDEKE H, GMELIN G, MALANOWSKI J. Brain selective approach to therapy for Alzheimer's disease. Prog Brain Res 1993: 98: 431-8.
7. WEINSTOCK M, RAZIN M, CHOREV M, ENZ A. Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors. J Neural Transm Suppl 1994: 43: 219-25.
8. SRAMEK JJ, ANAND R, WARDLE TS, IRWIN P, HARTMAN RD, CUTLER NR. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci 1996: 58: 1201-7.
9. CUTLER NR, SRAMEK JJ. Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study. Eur J Clin Pharmacol 1995: 48: 421-8.
10. CUTLER NR, SRAMEK JJ, VEROFF AE. Alzheimer's Disease: Optimizing Drug Development Strategies. Chichester: Wiley & Sons, 1994.
11. SRAMEK JJ, HURLEY DJ, WARDLE TS et al. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995: 35: 800-6.
12. BODICK NC, OFFEN WW, LEVEY AI et al. The effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease. Arch Neurol 1997: 54: 465-73.
13. VEROFF AE, CUTLER NR, SRAMEK JJ et al. A new assessment tool for research: the Computerized Neuropsychological Test Battery (CNTB). J Geriatr Psychiatry Neurol 1991: 4: 211-17.
14. POLINSKY RJ, JIMERSON DC, KOPIN IJ. Chronic autonomic failure: CSF and plasma 3-methoxy-4-hydroxyphenylglycol. Neurology 1984: 34: 979-83.
15. CUTLER NR, HAXBY J, KAY AD et al. Evaluation of zimeldine in Alzheimer's disease: cognitive and biochemical measures. Arch Neurol 1985: 42: 744-8.
16. POLINSKY RJ, BROWN RT, BURNS RS, HARVEY-WHITE J, KOPIN IJ. Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure. J Neurol Neurosurg Psychiatry 1988: 51: 914-19.
17. POLINSKY RJ, HOLMES KV, BROWN RT, WEISE V. CSF acetylcholinesterase levels are reduced in multiple system atrophy with autonomic failure. Neurology 1989: 39: 40-4.
18. POLINSKY RJ, HOOPER D, NEE L, MARINI A, SCOTT J. CSF corticotrophin releasing factor in patients with autonomic failure. Neurology 1991: 41 (Suppl. 1): 283.
19. ELLMAN GL, COURTNEY KD, ANDRES V. FEATHERSTONE RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961: 7: 88-95.
20. HALLACK M, GIACOBINI E. A comparison of the effects of two inhibitors on brain cholinesterase. Neuropharmacology 1987: 26: 521-30.
21. HALLACK M, GIACOBINI E. Physostigmine, tacrine, and metrifonate: the effect of multiple dosage on acetylcholine in rat brain. Neuropharmacology 1989: 28: 199-206.
22. CHUBB IW, GOODMAN S, SMITH AD. Is acetylcholinesterase secreted from central neurons into cerebrospinal fluid? Neuroscience 1976: 1: 57-62.
23. ATACK JR, PERRY EK, BONHAM JR, PERRY RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in human plasma and cerebrospinal fluid. J Neurochem 1987: 48: 1845-50.
24. YAKSH TL, FILBERT MG, HARRIS LW, YAMAMURA HI. Acetylcholinesterase turnover in brain, cerebrospinal fluid, and plasma. J Neurochem 1975: 25: 853-60.
25. ANAND R, GHARABAWI G, ENZ A. Efficacy and safety results of the early phase studies with Exelon® (ENA-713) in Alzheimer's Disease: an overview. J Drug Dev Clin Pract 1996: 8: 109-16.